GENFIT
ISIN: FR0004163111 | Ticker: GNFT | LEI: 969500XPWN2DMZQA5X73
Country: France
GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases. GENFIT is a pioneer in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades.
Today, GENFIT has a robust and diversified pipeline, using different compounds and technologies evaluated at different development stages and in different liver diseases.
Leveraging its internal assets and in-house expertise, GENFIT’s R&D is focused on cholestatic diseases and Acute on Chronic Liver Failure (ACLF): two therapeutic areas with significant unmet medical needs. Currently, the ELATIVE™ Phase 3 clinical trial is evaluating elafibranor (elafibranor is an investigational compound that has not been reviewed nor been approved by a regulatory authority) in patients with Primary Biliary Cholangitis (PBC) following a successful Phase 2 clinical trial.
1999
Served areaWorldwide
Headcount120
HeadquartersParc Eurasanté 885 Avenue Eugène Avinée, 59120 Loos – France
| Line item in (eur) | 01.01.2019 | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Assets | N/A | N/A | 198,119,000.00 | 281,720,000.00 | 215,540,000.00 |
| Noncurrent Assets | N/A | N/A | 13,403,000.00 | 13,623,000.00 | 57,081,000.00 |
| Property Plant And Equipment | N/A | N/A | 11,648,000.00 | 9,015,000.00 | 8,210,000.00 |
| Intangible Assets Other Than Goodwill | N/A | N/A | 297,000.00 | 174,000.00 | 43,957,000.00 |
| Noncurrent Receivables | N/A | N/A | 0.00 | 3,000.00 | 0.00 |
| Deferred Tax Assets | N/A | N/A | 0.00 | 0.00 | 0.00 |
| Other Noncurrent Financial Assets | N/A | N/A | 1,458,000.00 | 4,431,000.00 | 4,914,000.00 |
| Current Assets | N/A | N/A | 184,717,000.00 | 268,097,000.00 | 158,459,000.00 |
| Trade And Other Current Receivables | N/A | N/A | 11,919,000.00 | 7,236,000.00 | 15,906,000.00 |
| Other Current Financial Assets | N/A | N/A | N/A | 0.00 | 4,550,000.00 |
| Other Current Nonfinancial Assets | N/A | N/A | 1,765,000.00 | 2,101,000.00 | 1,998,000.00 |
| Cash and cash equivalents | N/A | 276,748,000.00 | 171,029,000.00 | 258,756,000.00 | 136,001,000.00 |
| Equity And Liabilities | N/A | N/A | 198,119,000.00 | 281,720,000.00 | 215,540,000.00 |
| Equity | 20,939,000.00 | 84,065,000.00 | -16,430,000.00 | 119,097,000.00 | 94,528,000.00 |
| Issued Capital | N/A | N/A | 9,722,000.00 | 12,454,000.00 | 12,459,000.00 |
| Retained Earnings | N/A | N/A | -303,897,000.00 | -405,076,000.00 | -337,550,000.00 |
| Share Premium | N/A | N/A | 379,057,000.00 | 444,438,000.00 | 444,683,000.00 |
| Equity Attributable To Owners Of Parent | N/A | N/A | -16,430,000.00 | 119,097,000.00 | N/A |
| Noncontrolling Interests | N/A | N/A | 0.00 | 0.00 | N/A |
| Noncurrent Liabilities | N/A | N/A | 183,482,000.00 | 99,786,000.00 | 81,641,000.00 |
| Noncurrent Provisions For Employee Benefits | N/A | N/A | 922,000.00 | 864,000.00 | 782,000.00 |
| Noncurrent Payables | N/A | N/A | 450,000.00 | 450,000.00 | 448,000.00 |
| Noncurrent Deferred Income Other Than Noncurrent Contract Liabilities | N/A | N/A | N/A | 25,821,000.00 | 9,706,000.00 |
| Deferred Tax Liabilities | N/A | N/A | 767,000.00 | 602,000.00 | 510,000.00 |
| Other Noncurrent Nonfinancial Liabilities | N/A | N/A | 11,873,000.00 | 24,365,000.00 | 20,334,000.00 |
| Longterm Borrowings | N/A | N/A | 169,470,000.00 | 47,682,000.00 | 49,861,000.00 |
| Current Liabilities | N/A | N/A | 31,067,000.00 | 62,837,000.00 | 39,370,000.00 |
| Current Provisions | N/A | N/A | 1,031,000.00 | 313,000.00 | 61,000.00 |
| Trade And Other Current Payables | N/A | N/A | 25,564,000.00 | 40,988,000.00 | 14,845,000.00 |
| Current Deferred Income Other Than Current Contract Liabilities | N/A | N/A | N/A | 14,298,000.00 | 14,479,000.00 |
| Other Current Financial Liabilities | N/A | N/A | 3,035,000.00 | 1,773,000.00 | 4,665,000.00 |
| Current Debt Instruments Issued | N/A | N/A | 1,312,000.00 | 415,000.00 | 415,000.00 |
| Line item in (eur) | 01.01.2019/ 01.01.2020 |
01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|---|
| Revenue | N/A | 7,758,000.00 | 85,579,000.00 | 26,566,000.00 |
| Other Revenue | N/A | 6,993,000.00 | 5,510,000.00 | 6,371,000.00 |
| Revenue From Contracts With Customers | N/A | 765,000.00 | 80,069,000.00 | 20,195,000.00 |
| Profit Loss From Operating Activities | N/A | -82,897,000.00 | 31,816,000.00 | -27,289,000.00 |
| Finance Income | N/A | 6,544,000.00 | 44,780,000.00 | 8,212,000.00 |
| Finance Costs | N/A | 25,296,000.00 | 7,122,000.00 | 4,758,000.00 |
| Profit Loss Before Tax | N/A | -101,649,000.00 | 69,474,000.00 | -23,836,000.00 |
| Income Tax Expense Continuing Operations | N/A | -428,000.00 | 2,215,000.00 | -116,000.00 |
| Profit (loss) | -65,144,000.00 | -101,221,000.00 | 67,259,000.00 | -23,719,000.00 |
| Profit Loss Attributable To Owners Of Parent | N/A | -101,221,000.00 | 67,259,000.00 | N/A |
| Profit Loss Attributable To Noncontrolling Interests | N/A | 0.00 | 0.00 | N/A |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | -65,144,000.00 | -101,221,000.00 | 67,259,000.00 | -23,719,000.00 |
| Adjustments For Income Tax Expense | N/A | -428,000.00 | 2,215,000.00 | -116,000.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 3,559,000.00 | 2,742,000.00 | 1,832,000.00 |
| Adjustments For Sharebased Payments | N/A | 1,236,000.00 | 470,000.00 | 245,000.00 |
| Other Adjustments For Noncash Items | N/A | -1,818,000.00 | -35,538,000.00 | 2,210,000.00 |
| Adjustments For Losses Gains On Disposal Of Noncurrent Assets | N/A | 80,000.00 | 420,000.00 | -16,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 0.00 | 0.00 | 145,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -96,371,000.00 | 99,915,000.00 | -72,638,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | N/A | 0.00 | 309,000.00 | 20,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 900,000.00 | 537,000.00 | -251,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -966,000.00 | -3,377,000.00 | -46,266,000.00 |
| Proceeds From Issuing Shares | N/A | 7,000.00 | 27,972,000.00 | 5,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 0.00 | 15,270,000.00 | 0.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 2,150,000.00 | 1,887,000.00 | 1,120,000.00 |
| Interest Paid Classified As Financing Activities | N/A | 7,762,000.00 | 2,109,000.00 | 2,180,000.00 |
| Cash Flows From Used In Financing Activities | N/A | -8,256,000.00 | -8,916,000.00 | -3,786,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | -105,593,000.00 | 87,622,000.00 | -122,690,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -126,000.00 | 105,000.00 | -66,000.00 |
| Cash and cash equivalents | 276,748,000.00 | 171,029,000.00 | 258,756,000.00 | 136,001,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 07.07.23 | None | Other | Buy | EUR 19,488.10 |
| 06.07.23 | None | Other | Buy | EUR 4,048.00 |
| 05.07.23 | None | Other | Buy | EUR 37,061.00 |
| 03.07.23 | None | Other | Buy | EUR 18,769.95 |
FR0004163111
LEI969500XPWN2DMZQA5X73
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.